Animal health market: A high revenue generating industry with revenue crossing US$ 112.0 billion by 2030 - Analyzed on Horizon Databook by Grand View Research, Inc.
SAN FRANCISCO, July 3, 2024 /PRNewswire/ -- Increasing pet ownership and the trend of treating pets as family members, the rising demand for livestock products due to a growing global population, and the need to manage zoonotic diseases to protect public health are some factors driving the animal health market. The global animal health market was valued at US$ 66.0 billion in 2023 and is likely to grow at a CAGR of 9.0% from 2025 to 2030 as reported by Grand View Research, Inc.
Technological advancements in diagnostics, biotechnology, and digital health tools enhance disease detection and treatment, while stringent regulatory environments ensure the safety and efficacy of health products. Economic growth, especially in emerging markets, leads to higher spending on pet and livestock care, and improvements in veterinary infrastructure enhance access to healthcare services. Lastly, ongoing research and development efforts drive innovation in treatments and preventive measures, contributing to overall market growth.
Horizon has a wide array of animal health topics within its database. Here are the top 10 trending animal health markets:
Diagnosis, as in all healthcare markets, plays a pivotal role. The companion animal health industry worldwide is expected to reach a projected revenue of US$ 42,495.7 million by 2030. A compound annual growth rate of 8.8% is expected of the worldwide companion animal health industry from 2023 to 2030.
AI has some groundbreaking impact on healthcare. We estimate the same in animal healthcare. Artificial intelligence (AI) in the animal health industry worldwide is expected to reach a projected revenue of US$ 3,764.0 million by 2030. A lucrative compound annual growth rate of 19.1% is expected of the worldwide artificial intelligence (AI) in the animal health industry from 2024 to 2030.
This veterinary medicine market is projected to demonstrate growth (CAGR - 2024 to 2030) of 8.2% to reach an estimated revenue of US$ 80 billion in 2030.
About Horizon Databook ? The most extensive market research database
Horizon Databook is the largest market research database with over 1 million data points across 20,000+ markets. The platform is first-in-class and is designed to service a full suite of market research clients. It is a one, five solution platform and includes the following:
Over 1 million market statistics: Global, regional and country (25+) statistics focusing on revenue, volume and growth spanning across a timeline of 10 years form the core of this platform.
The platform hosts over 25,000 market reports ready to be downloaded or viewed online in an HTML format. These reports are a comprehensive analysis of a market and cover everything from market statistics, drivers and restraints to detailed company analyses.
5 million+ companies: Detailed financial performance, deals and latest news are all an integral part of Horizon. We have partnered with industry pioneers to provide accurate and latest competitive data.
Viridian Therapeutics, Inc. (the "company" or "Viridian"), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent...
Neuromod Devices Ltd. (Neuromod), the global medical technology business that created the first and only FDA Approved tinnitus treatment device, Lenire, has today announced the appointment of Tom Maher as General Counsel, effective July 5, 2024....
The "Annual GMP Master Class 2024" training has been added to ResearchAndMarkets.com's offering.
cGMPs or Current Good Manufacturing Practices is a general encompassing term for the regulations that the control of all facets of life sciences...
The Canadian Dermatology Association (CDA) is proud to announce this year's recipients of its Member Awards and Public Education Awards, following a detailed review of nominations received by the Membership and Awards Committee using a thorough...
IntelGenx Corp. (the "Company" or "IntelGenx" a subsidiary of IntelGenx Technologies Corp.) , has successfully completed the BUENA Alzheimer's disease (AD) study. The BUENA study was designed as a Phase 2a proof of concept study to investigate the...